
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically high levels, driven by new funding and strategic transactions, especially within oncology, according to a new research report Global Trends in R&D: Overview Through 2020 released by the IQVIA Institute for Human Data Science.
Key highlights of the report include:
For more information, click






